OncoMatch/Clinical Trials/NCT05770102
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Is NCT05770102 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Atezolizumab for malignancy.
Treatment: Atezolizumab — This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage small cell lung cancer, hepatocellular carcinoma and triple negative breast cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Atezolizumab works in patients with these types of cancers which have certain changes in the cancer cells called high tumour mutational burden (TMB) or high microsatellite instability (MSI) or proven (previously diagnosed) constitutional mismatch repair deficiency (CMMRD). Investigators now wish to find out if it will be useful in treating patients with other cancer types which are also TMB/MSH-high or show CMMRD. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future. This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Endometrial Cancer
Melanoma
Prior therapy
Cannot have received: same class of drug (immune checkpoint inhibitor)
Exception: unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to atezolizumab
Prior treatment with the same class of drug unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to atezolizumab
Cannot have received: allogeneic stem cell or solid organ transplantation on immunosuppression
Prior allogeneic stem cell or solid organ transplantation on immunosuppression
Lab requirements
Blood counts
Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol
Kidney function
Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol
Liver function
Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol
ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. PAEDIATRIC PATIENTS (<18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify